AMS BioteQ Showcases Game-Changing Innovations at Medical Japan 2024

AMS BioteQ (Stock Code: 6864) has made its mark in Japan with innovative technology and flexible production capabilities. This year, the company participated in Medical Japan 2024, showcasing its latest healthcare solutions, including medical wound care dressings, post-operative recovery products, and cutting-edge drug development achievements. Dr. Yiju Tsai, founder and Chairman of AMS BioteQ, highlighted the company’s international strategy, core technologies, and market presence in Japan during the exposition.

Strengthening Global Presence: Targeting the Japanese Healthcare Market

AMS BioteQ’s main goal at Medical Japan 2024 was to promote its key areas: innovative medical materials, post-operative recovery products, and drug development. Dr. Tsai shared that the company aims to achieve four primary objectives through this exhibition: enhancing brand reputation, connecting with Japan’s drug and medical dressing markets, finding distribution partners, and pursuing collaborations in drug development.

“We hope to establish a solid foundation in the Japanese market and use it as a basis for expanding globally,” said Dr. Tsai. Participation in this exhibition is pivotal for AMS BioteQ’s entry into Japan, especially in drug research, medical devices, and healthcare products. The company’s unique technology and scalable production capabilities are expected to attract both local and international partners.

Rising Demand in Chronic Wound Care Market

The global chronic wound care market is rapidly expanding due to factors like the high incidence of diabetes, an aging population, and improved detection of chronic wounds. These include diabetic foot ulcers, arterial ulcers, venous ulcers, and pressure ulcers, all of which are difficult to heal within three months. According to recent data, the global chronic wound care market is projected to grow from USD 14.17 billion in 2024 to USD 24.03 billion by 2032, with a compound annual growth rate (CAGR) of 6.8%. The increasing elderly population and rising diabetes rates are driving demand for chronic wound care solutions.

Innovative SIPSIP Foam Dressing Secures PMDA Approval

AMS BioteQ focuses on “moist wound healing” and has successfully launched two primary products: SIPSIP Foam and SIPSIP Pro Gel Dressings. SIPSIP Foam offers high absorption, softness, and easy removal, making it ideal for various wound types, particularly for elderly patients. Meanwhile, SIPSIP Pro Gel Dressing emphasizes deep wound healing with scar-free, painless, and eco-friendly properties, incorporating aesthetic medicine techniques for broader applications.

“Japan’s aging society has a significant demand for medical devices, especially wound care products, and our offerings meet this market need,” emphasized Dr. Tsai. These dressings are particularly suitable for elderly burn patients and chronic wounds, effectively accelerating healing and reducing infection risks. Additionally, SIPSIP Pro serves the aesthetic medicine post-operative care market, especially for quick recovery following laser treatments.

Building Bridges in Japan: High Standards, High Rewards

Dr. Tsai noted that the Japanese market is crucial, not only due to its aging population and high healthcare standards but also for its openness to innovative technologies. “While there are high entry barriers, the quality requirements create greater international opportunities once a company establishes a presence,” he stated.

This year marked AMS BioteQ’s second participation in the exposition, engaging with numerous Japanese academic and research institutions. According to RX Japan, over 70% of visitors at Medical Japan are local. To facilitate effective communication, AMS BioteQ deployed a team fluent in Japanese, underscoring its commitment to understanding the local market and culture. Dr. Tsai also highlighted the importance of showcasing technical innovation to meet the high standards of Japanese clients.

Conclusion: Expanding Horizons in Global Healthcare

In summary, AMS BioteQ has attracted attention in Japan with its innovative dressing technology, antibody-drug conjugate (ADC) technology, and advancements in post-operative recovery solutions. As collaborations with Japanese pharmaceutical companies progress, AMS BioteQ is poised to establish a strong presence in Japan and expand its technologies globally, aiming for broader market impact.

For more information, please visit AMS BioteQ’s official website and LinkedIn.

Author

Oscar Wu